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Background: Growing evidence suggests that DNA methylation plays a role in tissue-specific differentiation.
Current approaches to methylome analysis using enrichment with the methyl-binding domain protein (MBD) are
restricted to large (≥1 μg) DNA samples, limiting the analysis of small tissue samples. Here we present a technique
that enables characterization of genome-wide tissue-specific methylation patterns from nanogram quantities of DNA.
Results: We have developed a methodology utilizing MBD2b/MBD3L1 enrichment for methylated DNA, kinase
pre-treated ligation-mediated PCR amplification (MeKL) and hybridization to the comprehensive high-throughput array
for relative methylation (CHARM) customized tiling arrays, which we termed MeKL-chip. Kinase modification in
combination with the addition of PEG has increased ligation-mediated PCR amplification over 20-fold, enabling >400-
fold amplification of starting DNA. We have shown that MeKL-chip can be applied to as little as 20 ng of DNA,
enabling comprehensive analysis of small DNA samples. Applying MeKL-chip to the mouse retina (a limited tissue
source) and brain, 2,498 tissue-specific differentially methylated regions (T-DMRs) were characterized. The top five
T-DMRs (Rgs20, Hes2, Nfic, Cckbr and Six3os1) were validated by pyrosequencing.
Conclusions: MeKL-chip enables genome-wide methylation analysis of nanogram quantities of DNA with a wide
range of observed-to-expected CpG ratios due to the binding properties of the MBD2b/MBD3L1 protein complex. This
methodology enabled the first analysis of genome-wide methylation in the mouse retina, characterizing novel T-DMRs.
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DNA methylation is an epigenetic modification known
to be important in many cellular processes, including
tissue-specific gene expression. There is no standardized
method for DNA methylation analysis and most array-
based methods for genome-wide profiling require input
DNA in microgram quantities, making them impractical
for small tissue samples (Table 1). Sodium bisulfite mod-
ification is traditionally considered the gold-standard
technique for assessing methylation [1]. Alternatives to
bisulfite conversion include enrichment of methylated/* Correspondence: smerbs@jhmi.edu
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reproduction in any medium, provided the orunmethylated DNA by the use of methylation-sensitive
restriction enzymes (MREs, for example, HpaII), immu-
noprecipitation with an anti-5-methylcytosine antibody
(MeDIP) or affinity enrichment with methyl-binding
domain proteins (MBDs) (Table 1). After bisulfite con-
version or enrichment, DNA methylation can be quanti-
fied via next-generation sequencing or hybridization to
a microarray. While whole genome bisulfite sequenc-
ing (WGBS) can quantify DNA methylation at single-
nucleotide resolution using nanogram amounts of DNA,
it requires robust bioinformatics resources, and the current
cost-per-sample is still relatively high; thus, alternative
methods to perform targeted bisulfite sequencing, such as
reduced-representation bisulfite sequencing (RRBS) have
been developed [2]. The single-nucleotide resolution oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.





WGBS [6-8] 0.01–0.1 Illumina
MeDIP-Seq [3,4] 0.05–0.3 Illumina
MBD-Seq [3] 1a Illumina
RRBS-Seq [3,9] 0.01–0.05 Illumina
MRE-Seq [10] 3 Illumina
MeDIP-Chip [11] 4 Affymetrix promoter array
MBD-Chip [11] 1 Affymetrix promoter array




CHARM [14] 10 NimbleGen
MeKL-Chip 0.02 NimbleGen/any
aPooled four to eight 1-μg fractions.
bNot available for the mouse genome.
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compared to MeDIP and MBD enrichment-based methods
[3,4]. The most common MBD enrichment uses MBD2b,
which shows high affinity for double-stranded, methylated
DNA, in contrast to the MeDIP antibody, which binds
methylated single-stranded DNA. The binding affinity of
MBD2b is sequence independent, and MBD enrichment
can be further enhanced by the addition of MBD3L1.
Methylated-CpG island recovery assay (MIRA) [5] uses
this protein complex and is now commercially available as
a kit. Direct next-generation sequencing comparison has
shown that MBD enrichment can identify more differen-
tially methylated regions (DMRs) than either RRBS or
MeDIP [3], but it is currently an underutilized method-
ology, particularly in combination with the more econom-
ical array-based analyses.
Methylation data obtained by hybridization to pro-
moter, CpG island or CpG site-specific microarrays is
biased and restricted by the design of the array platform.
To overcome this bias, the comprehensive high-throughput
array for relative methylation (CHARM) platform was de-
veloped to interrogate CpG sites genome-wide, irrespective
of proximity to genes or CpG islands [14]. As the CHARM
array was designed such that the genome coverage is driven
by sequence and is not based on assumptions about CpG
site location, it provides greater genome-wide coverage
than other array platforms typically used for methylation
analysis. The CHARM method enriches for unmethylated
DNA using McrBC restriction enzyme digestion, which is
compared to input DNA on a custom NimbleGen 2.1 mil-
lion feature tiling array platform. Using this approach,
tissue-specific differentially methylated regions (T-DMRs)
have been detected in humans, mice and rats, including
regions of low CpG density [15,16], which would normallybe excluded from promoter and CpG island arrays. How-
ever, applicability of the McrBC-based CHARM protocol is
limited because the enrichment protocol requires large
amounts (10 μg) of starting genomic DNA (Table 1).
While MIRA can enrich DNA samples in the nanogram
range [5], hybridization to the 2.1M NimbleGen microarray
requires 1 μg of each DNA sample post-enrichment, ne-
cessitating high-magnitude whole genome amplification
(WGA). There are two categories of commonly used WGA
methodology: PCR amplification and isothermal DNA am-
plification. Ligation-mediated PCR (LM-PCR) [17] falls into
the former category and involves the ligation of a unidirec-
tional, double-stranded oligonucleotide universal adapter to
blunted DNA fragments. The universal primer sequence
can then be used to amplify all ligated fragments via PCR.
LM-PCR enables amplification of a range of small PCR
fragments (up to 2,000 bp in length), irrespective of the
genomic sequence.
Currently, no protocols are available for MBD-chip with
low amounts of starting DNA. With the goal of estab-
lishing a user-friendly method for assessing genome-wide
DNA methylation in small (nanogram) DNA samples, we
developed a new protocol based upon MBD2b/MBD3L1
enrichment [5] followed by amplification using modified
LM-PCR, which we call MeKL-chip. The development of
an array-based method for small tissue samples is advanta-
geous for global methylation analysis because it does not
have the computational burden of sequencing-based
methods. Here we report on our MeKL-chip assay, its ap-
plication to the mouse retina (a limited tissue source), and
highlight its ability to detect novel T-DMRs with a wide
range of CpG densities.
Results
Improved amplification efficiency by modified
ligation-mediated PCR
Using the published LM-PCR protocol as a starting point
[17], we explicitly tailored our amplification for nanogram
levels of input DNA. As LM-PCR can be limited by the
efficiency of the ligation reaction, we made two modifica-
tions to improve the ligation reaction. Firstly, we increased
the efficiency by adding a pre-ligation kinase treatment
(kinase-modified ligation-mediated PCR, KLM-PCR) to
repair DNA damage induced during fragmentation. Soni-
cation can result in DNA breaks with 5′ hydroxyl and
3′ phosphate; treatment with T4 polynucleotide kinase re-
instates the 5′ phosphate and 3′ hydroxyl moieties. This
increased the amount of the template for ligation, improv-
ing the amplification 14-fold over the published method
(Figure 1A). Additionally, we incorporated higher poly-
ethylene glycol (PEG-8000) concentrations (12.5% or 15%
vs 5%) in the ligation reaction buffer, as a previous report
showed improved ligation efficiency under these conditions
[18]. PEG-8000 concentrations of 12.5% and 15% increased
Figure 1 Improvements achieved by the KLM-PCR protocol and an overview of the MeKL-chip method. (A) Quantitative PCR assessment
of fold increase in amplification using KLM-PCR with oligo_1 (dark grey) and Rbp3 primers (light grey) as a direct comparison to the standard
LM-PCR protocol (no kinase, 5% PEG-8000) using different amounts of PEG-8000 (%), with (+) and without (−) kinase treatment. The relative
improvement of each reaction was calculated as a fold-change in comparison to the standard LM-PCR protocol. Amplification at Rbp3 was used
as a between-conditions loading control. Error bars based on standard error of the mean (n = 5). (B) Overview of the MeKL-chip method with the
procedures for the input and enriched DNA as marked. The optional quality control steps are indicated by dashed arrows. KLM-PCR:
kinase-modified ligation-mediated PCR; LM-PCR: ligation-mediated PCR; MeKL: MBD2b/MBD3L1 enrichment of DNA followed by KLM-PCR.
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Combined, these modifications increased the amplification
24- to 38-fold. Due to the difficulty of working with the vis-
cous 15% PEG solution, we elected to use 13% PEG for
subsequent experiments. To maximize PCR efficiency, a
palindrome within the universal adapter sequence was
disrupted to prevent the formation of an adapter-only
template (Additional file 1: Figure S1A). We termed this
combination of MBD2b/MBD3L1 enrichment [5] of DNA
followed by KLM-PCR and subsequent hybridization to
a microarray platform MeKL-chip (Figure 1B). MeKL
can be used successfully to amplify sufficient DNA for
microarray labeling and hybridization from as little as 10 ng
of pre-enrichment, fragmented DNA (Additional file 1:
Figure S1B).Identification of T-DMRs using MeKL-chip
MeKL-chip was used to perform genome-wide profiling
of adult mouse retinas to identify retinal T-DMRs, using
the brain as a comparison neuronal tissue. As a quality
control to demonstrate successful MBD2b/MBD3L1 en-
richment of methylated DNA, quantitative PCR (QPCR)
was performed at regions known to be differentially
methylated between the retina and brain. The retinol-
binding protein 3 (Rbp3) and rhodopsin (Rho) genes are
specifically expressed in retinal photoreceptors and have
been shown to be hypomethylated in a cell-specific man-
ner in the retina compared to non-retinal tissues [19]. In
addition to QPCR validation of Rho and Rbp3, the
imprinted gene H19 (which is fully methylated on the
paternal allele [20]) was also examined to ensure equal en-
richment of methylated DNA in the retina and brain sam-
ples. After MBD enrichment, samples showed differential
amplification of Rho and Rbp3 in the brain compared tothe retina, and a lack of differential enrichment of H19 be-
tween the retina and brain (Figure 2A). The differential en-
richment pattern between the retina and brain was
maintained after KLM-PCR (Figure 2B). The amplified
methylation-enriched and unenriched DNA from each
sample were labeled and co-hybridized to the mouse
CHARM array. In total, 2,498 novel T-DMRs were identi-
fied of which 1,449 were hypermethylated in the brain
(Additional file 2: Table S1).
Validation of potential T-DMRs by pyrosequencing
The top five T-DMRs were validated by pyrosequencing
(Figure 2C and Additional file 3: Figure S2). The highest
ranking T-DMR, which was hypermethylated in the
retina, covered Exon 3 of Rgs20 and its flanking introns
(Figure 2C). An alternative transcription start site is
located at Exon 3, an exon which is included in the
brain-specific isoform of Rgs20 and excluded from the
retina-specific isoform [21]. The remaining top T-DMRs
(associated with genes Hes2, Nfic, Cckbr and Six3os1) over-
lapped transcription start sites or were located intragen-
ically (Additional file 3: Figure S2). The directionality of the
differential methylation at all T-DMRs identified by MeKL-
chip was completely consistent with the methylation levels
observed in an independent mouse cohort by bisulfite
pyrosequencing.
Local CpG density and observed-to-expected CpG ratio
analysis at T-DMRs
To assess the properties of the MBD2b/MBD3L1 enrich-
ment within the MeKL-chip assay, the CpG density and
the observed-to-expected CpG ratios (CpGO/E) were
determined for all T-DMRs identified. T-DMRs with a
wide range of local CpG densities (1.7 to 46.2 in a 300
Figure 2 Application of MeKL-chip to identify T-DMRs in the mouse retina and brain. The fold-change between the retina and brain DNA
samples was calculated and combined for samples used for MeKL-chip. The mean fold enrichment and standard error of the mean are plotted
for triplicate enrichment experiments (three mice, three DNA samples). (A) Post-MBD enrichment, QPCR showed Rbp3 (grey) and Rho (black) were
enriched for methylated DNA in the brain samples as expected. Also as expected, no differential enrichment was evident for H19 (white).
(B) Post-KLM-PCR, QPCR showed maintenance of the enrichment pattern for methylation in the brain samples for Rho and Rbp3, while the
amount of the H19 template remained equal in both tissues. (C) Relative CpG methylation profiles as evaluated using MeKL-chip (top) and
pyrosequencing validation (bottom) of the top T-DMR at Rgs20 for the brain (blue, dashed) and retina (red, solid) from 250 ng of starting DNA.
Each point is the relative methylation at one probe from one sample; blue and red lines show the average methylation of triplicates. Near the
highest ranked T-DMR (black box, P < 10-16) is a second T-DMR (P < 0.0091, dashed box). The alternative TSS of the brain-specific isoform of Rgs20
is indicated by a dashed arrow at Exon 3. Bisulfite pyrosequencing of seven CpGs within Intron 2 confirmed differential methylation between the
mean of retina (red bars) and brain (blue bars) in five mice (Student’s two-tailed, paired t-test, P < 0.001). Error bars show the 95% CI (n = 5).
KLM-PCR: kinase-modified ligation-mediated PCR; MBD: methyl-binding domain protein; MeKL: MBD2b/MBD3L1 enrichment of DNA followed by
KLM-PCR; QPCR: quantitative PCR; T-DMR: tissue-specific differentially methylated region; TSS: transcription start site.
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(Figure 3A,B). The majority of the T-DMRs were located
in regions with relatively low CpG content (mean local
CpG density of 9.2, mean CpGO/E of 0.39). An example
of the diversity of CpG densities detectable within a gen-
omic locus was found at the Rbp3 gene, which is hyper-
methylated in brain tissue [19]. Three T-DMRs were
identified within a 3,000 bp region of Rbp3 with local
CpG densities of 4.6, 9.4 and 13.2 and CpGO/Es of 0.31,
0.38 and 0.47, respectively (Figure 3C).MeKL-chip for nanogram DNA samples
To determine the effectiveness of MeKL-chip on low-
input DNA samples, differing amounts of total starting
DNA were fragmented, enriched and amplified from
mouse retina and brain. Successful fragmentation was
achieved with 50, 125 and 250 ng of sample DNA (data
not shown). MBD2b/MBD3L1 enrichment was achieved
using as little as 10 ng of fragmented sample DNA
(Additional file 4: Figure S3A). Enrichment was main-
tained after KLM-PCR amplification in all low-input
Figure 3 MBD2 enrichment by MeKL-chip enables detection of differential methylation over a range of CpG densities and CpGO/Es.
(A) CpG density and (B) CpGO/E at each T-DMR was calculated over a 300 bp window. A range of CpG densities was observed, but the majority
of T-DMRs were within low-CpG density regions. (C) Three T-DMRs (black boxes) associated with the retina-specific gene Rbp3 for the retina
(red, solid) and brain (blue, dashed) are shown. The TSS (arrow) and a portion of Exon 1 are shown in grey. The three T-DMRs had varying CpGO/
Es: 0.31 (left box), 0.38 (central box) and 0.47 (right box), and local CpG densities: 4.6 (left box), 9.4 (center box) and 13.2 (right box). CpGO/E:
observed-to-expected CpG ratio; MeKL: MBD2b/MBD3L1 enrichment of DNA followed by KLM-PCR; T-DMR: tissue-specific differentially methylated
region; TSS: transcription start site.
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chip data of the Rgs20 region from the 10-ng input sam-
ples from the retina and brain revealed tissue-specific
methylation differences comparable to those detected in
the 250-ng arrays (Additional file 5: Figure S4). Array
hybridization of the 10, 25 and 50 ng fragmented and
MBD2b/MBD3L1-enriched DNA from retina and brain
samples yielded analyzable results that were combined to
provide a low-input MeKL-chip group. The difference in
methylation between retina and brain (ΔM) at T-DMRs
identified within the high-input samples (250 ng) was com-
pared to the corresponding ΔM of these same T-DMRs
from the low-input samples (10, 25 and 50 ng; Figure 4A).
A strong correlation was observed between the high- and
low-input results (correlation coefficient [c.c.] = 0.63, 0.59
and 0.75, respectively). In comparison, there was no correl-
ation between high- and low-input experiments when the
probe positions were randomly shuffled (Figure 4B). Over
61% of the 2,498 T-DMRs identified in the high-input
samples had the same directionality of ΔM for all three
low-input samples, which were termed ‘verified’ T-DMRs.
The remaining T-DMRs showed inconsistent ΔM direc-
tions between the high- and low-input groups (visible inthe upper left and lower right quadrants of Figure 4A), and
were referred to as ‘dropouts.’ Notably, the majority (72%)
of these dropout T-DMRs had an opposite ΔM direction
in only one of the three low-input samples and less than
11% of all 2,498 T-DMRs had a conflicting ΔM direction
with two or more low-input samples. The dropouts tended
to have lower CpGO/E and lower CpG density (Figure 4C).
Integrative analysis of the T-DMR data with exon array
data in the same mouse tissues [22] revealed that only
6% of these dropouts were associated with retina-/brain-
enriched genes when filtering for those dropouts absent
from at least two low-input arrays (Figure 4D). These re-
sults indicated that the low-input arrays were able to detect
differential methylation within biologically relevant regions
and validated the use of the MeKL-chip method on low-
input (≤50 ng) DNA samples.
Discussion
We have demonstrated a novel combination of MBD2b/
MBD3L1 enrichment, modified ligation-mediated PCR
amplification and microarray hybridization, in a method
termed MeKL-chip. Using our unique protocol, we
have shown that MeKL-chip permits genome-wide DNA
Figure 4 Comparison of T-DMRs from high- and low-input samples identified using MeKL-chip. (A) Correlation of differential methylation
between retina and brain (ΔM) from high- and low-input arrays at T-DMRs initially identified within the 250-ng samples. (B) Relationship between
ΔM of T-DMRs for high-input and that of randomly shuffled probes for the 10, 25 and 50 ng low-input arrays. (C) Distribution of CpGO/E
(top panel) and CpG density (bottom panel) of verified T-DMRs for all three low-input arrays, dropouts from only one low-input array, and
dropouts from at least two low-input arrays. (D) Percentage of T-DMRs and dropouts from at least two low-input arrays that were associated with
retina-/brain-enriched genes identified from previously published exon array data. c.c: correlation coefficient; CpGO/E: observed-to-expected CpG
ratio; MeKL: MBD2b/MBD3L1 enrichment of DNA followed by KLM-PCR; T-DMR: tissue-specific differentially methylated region.
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(comprising 10 ng for enrichment and 10 ng input for
comparison). The ability to study genome-wide methyla-
tion in small samples enabled us to identify novel T-
DMRs in a limited tissue sample: the mouse retina. The
MeKL-chip protocol fills a void in the currently available
methylation profiling technologies, enabling regional
examination of methylation patterns with a low compu-
tational requirement.
Ligation-mediated PCR (LM-PCR) is an approach well
suited to the amplification of small DNA fragments [17].
In LM-PCR, universal linkers are ligated to blunt-ended
DNA fragments, which are then used to amplify the li-
gated DNA via PCR [17]. We modified the LM-PCR
protocol to include a pre-ligation kinase step to repair the
fragmented DNA, included PEG during the ligation to in-
crease ligation efficiency and modified the linker sequence
to remove a palindrome. After these modifications, KLM-
PCR was able to produce sufficient DNA for microarray
hybridization (a minimum of 70-fold amplification) from
post-enrichment samples derived from as little as 10 ng.
The top five T-DMRs identified by MeKL-chip and vali-
dated by pyrosequencing were all genes with knownbiological relevance in the retina. The top T-DMR at
Rgs20 (regulator of G protein signaling 20, Gene ID:
58175) overlapped an alternative transcription start site
[21], which suggests that DNA methylation may play an
essential role in the tissue-specific expression of Rgs20
transcripts in the retina and brain. The location of the T-
DMR within Rgs20 is consistent with existing results that
have shown a role for intragenic DNA methylation in
tissue-specific expression mediated by alternative tran-
scriptional start sites [23]. The transcription factor Hes2
(hairy and enhancer of split 2, 15206) has been previously
implicated in cell fate determination of the Xenopus retina
[24], and Six3os1(100043902), a long non-coding RNA on
the opposite strand to the sine oculis-related homeobox 3
transcription factor, has also been described as important
during retinal development [25]. Cckbr (cholecystokinin B
receptor, 12426) mRNA has been reported in the rat retina
[26]. Nfic (nuclear factor I/C, 18029) has been described
as overexpressed in the retina of patients with proliferative
vitreoretinopathy, a disease where aberrant wound healing
occurs in the retina [27]. The ability to analyze global
DNA methylation in the mouse retina has identified T-
DMRs at biologically relevant genes in addition to novel
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these top T-DMRs identified in the high-input (250 ng) ar-
rays were also identified in the low-input (≤50 ng) arrays.
We observed that the overall difference in methylation
at the T-DMRs was greater by pyrosequencing than by
MeKL-chip. This difference in percentage methylation
between array hybridization and pyrosequencing has
been noted previously [15], suggesting that hybridization
to CHARM arrays using either unmethylated-enriched or
methylated-enriched DNA may underestimate the relative
difference in methylation between samples as a conse-
quence of the fixed dynamic range of microarrays.
One of the main advantages of using MBD2b/MBD3L1
enrichment, due to the unique binding properties of the
MBD2b/MBD3L1 complex, is the ability to detect methy-
lation within a wide range of CpG densities [11]. Although
MeKL-chip is unable to measure site-specific CpG methy-
lation compared to bisulfite-based sequencing methods,
we successfully identified robust T-DMRs throughout the
mouse genome. We were able to isolate T-DMRs with a
broad range of observed-to-expected CpG ratios and CpG
densities unlike the more frequently used MeDIP tech-
nique, which is known to be most efficient at low CpG
density ranges [11]. Although the CpGO/Es of our T-
DMRs ranged from 0.10 to 1.05, the majority of our T-
DMRs had CpGO/Es less than that of a CpG island
(CpGO/E > 0.6). This observation supports previously
published data indicating that the majority of T-DMRs are
identified in regions outside of CpG islands with relatively
low CpG density, for example, CpG shores and CpG
shelves [15,16,28,29]. While we selected the NimbleGen
CHARM 2.1M platform because regions of low CpG den-
sity were incorporated into the array design, the MeKL-
chip methodology is amendable to any array platform. The
incorporation of PEG during ligation should facilitate next-
generation sequencing library preparation from nanogram
amounts of methylation-enriched DNA.
Conclusions
We have demonstrated that the KLM-PCR method of
WGA results in greater than 400-fold amplification of
low-input DNA samples. This protocol has many poten-
tial downstream applications, including hybridization to
custom arrays as well as next-generation sequencing-
based platforms. By combining KLM-PCR WGA and
MBD-affinity methylation enrichment with hybridization
to a custom CHARM microarray (MeKL-chip), we were
able to achieve robust identification of T-DMRs between
the retina and brain within biologically relevant genes
using nanogram quantities of input DNA. The MeKL-chip
method enables genome-wide assessment of methylation
in samples previously considered below the threshold for
array-based, global methylation analyses. This methodology
will be particularly useful for the identification of regionalmethylation differences between small tissue samples,
for example, laser-capture microdissection collected DNA,
and in detecting disease-associated methylation differences
within affected cell layers.
Methods
Animals
Eight-week-old C57BL/6J male mice (n = 5) (Jackson La-
boratories) were euthanized using IsoSol™ (VEDCO) ex-
posure followed by neck dislocation. A second cohort of
eight-week-old C57/B6J male mice (n = 5) was processed
in an identical manner for validation using bisulfite
pyrosequencing. All procedures were approved by the
Johns Hopkins University Institutional Animal Care
and Use Committee (IACUC) and were performed in
accordance with guidelines in the National Research
Council’s Guide for the Care and Use of Laboratory
Animals.
Samples
After euthanasia, the mouse eyes were immediately enu-
cleated and placed into 1X PBS buffer. The cornea and
lens were discarded and the eyecup placed into 500 μL
of 1X Hanks’ balanced salt solution (HBSS, Invitrogen).
The eyecup was incubated for 15 min at 37°C and then
microdissected in 1X HBSS. Surrounding sclera was re-
moved from the retina, and any remnants of retinal pig-
ment epithelium were removed by gentle scraping. Three
samples of 25 mg of brain cortex were removed from each
mouse. DNA extraction was performed on each sample
using the DNeasy Blood and Tissue kit (Qiagen) following
the manufacturer’s protocols with addition of RNase A.
DNA was eluted in 400 μL Buffer AE. Ethanol precipita-
tion of the DNA samples was performed [30] and the
DNA resuspended in 40 μL 1X TE pH 8.0. Retina/brain
DNA samples originating from the same mouse were
pooled. The amount of DNA in each sample was quanti-
fied using the Quant-iT™ PicoGreen® dsDNA Assay Kit
(Invitrogen).
MBD enrichment for methylated DNA
Prior to enrichment, 2.5 μg of DNA in 100 μL 1X TE
pH 8.0 was fragmented to an average target size of 300
bp (duty cycle 10%, intensity 4, cycles per burst 200,
time 60 sec) using a Covaris™ S220 Ultrasonicator. For
smaller amounts of DNA, 50, 125 or 250 ng of DNA
was fragmented in 50 μL (duty cycle 10%, intensity 5,
cycles per burst 200, time 50 sec). The accuracy of the
fragmentation was checked using an Agilent 2100
Bioanalyzer with the DNA 1000 kit. Enrichment was
performed using the MethylCollector Ultra Kit (Active
Motif) according to the manufacturer’s protocols (version
C1) using Low-Salt Binding Buffer AM12. DNA cleanup
after enrichment was performed using the MinElute PCR
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in 10 μL Buffer EB. To enable quality control experiments,
fragmented DNA was enriched in duplicate and the dupli-
cate samples combined.
QPCR validation of enrichment
QPCR was performed for the known brain/retina differ-
entially methylated genes Rho (Gene ID 212541) and
Rbp3 (19661) [19] and a known equally methylated gene,
H19 (14955) [20]. QPCR was performed on an iQ™5 in-
strument (Bio-Rad) using 1X EvaGreen® dye (Biotium),
Fermentas Maxima™ Hot Start Taq DNA Polymerase
(Thermo Fisher Scientific) and 1.2 μL of 5 μM forward and
reverse primer mix in a final 20 μL reaction volume. Next,
10 ng of fragmented, unenriched DNA, 1 μL of post-
enrichment DNA or 10 ng post-amplification DNA were
amplified in triplicate for the same sample at all three genes.
The primer sequences were (5′ to 3′): Rho forward: AA
GCAGCCTTGGTCTCTGTC, Rho reverse: CCCTCTGTG
CCGTTCATGG, Rbp3 forward: GGCCCAGATACAGAG
GAACA, Rbp3 reverse: GCTCGCTCAGTACCTCTTGG,
H19 forward: TGTGTAAAGACCAGGGTTGC and H19
reverse: GGGAGAAAACTCAATCAGTTGC. The QPCR
cycling conditions were: 95°C for 3 min, 50 × (95°C for 10
sec, 66.4°C for 30 sec, 72°C for 30 sec) followed by the
standard dissociation steps. The mean threshold cycle (Ct)
for each sample was used to calculate ΔCt(retina-brain), and
ΔCt was then used to calculate the fold enrichment for
methylation (2ΔCt). A lower Ct for the brain sample and a
fold enrichment greater than 2 should be observed post-
enrichment as the brain is hypermethylated at Rho and
Rbp3 [19].
Whole genome amplification by kinase ligation-mediated
PCR
All buffers and enzymes used for amplification were from
New England Biolabs (NEB) unless otherwise stated.
Based on the LM-PCR protocol developed by the Ren la-
boratory [17], 5 μg of sonicated DNA was treated with
RNAse A followed by phenol:chloroform:isoamyl alcohol
extraction and purification with the MinElute PCR Purifi-
cation kit. Next 500 ng of the sonicated DNA was treated
with either 60 U of T4 Polynucleotide Kinase or mock
treated (no kinase added) in a final volume of 300 μL of
1X T4 DNA ligase buffer and 100 μg/mL BSA for 2 h at
37°C. To fill in the fragmented ends, 200 μL of cold
blunting mix containing 25 μL NEBuffer 3, 25 μL of dNTP
mix (10 mM each dNTP), 2 μL 10 mg/ml BSA and 7.5 U
of T4 DNA polymerase were added to each reaction and
incubated at 12°C for 30 min. Reactions were extracted
with phenol:chloroform:isoamyl alcohol, precipitated with
1 volume of isopropanol in the presence of 300 mM so-
dium acetate (pH 5.2) at −80°C overnight, washed twice
with 70% ethanol and resuspended in 500 μL of H2O.Modified linkers (KLM-PCR Oligo_1: 5´ GCG GTG ACC
CGG GAG ATC TGA GTT C 3´, Oligo_2: 5´ GAA CTC
AGATC 3´) [17] included a single base change (GAATTC
to GAGTTC) in KLM-PCR Oligo_1, which disrupted the
GAATTC palindrome thus improving the efficiency of the
PCR. To anneal the linkers, 510 μL of 40 μM Oligo_1 and
490 μL of 40 μM Oligo_2 were combined with 250 μL of
5X Duplex Buffer (100 mM Tris–HCl pH 8.0, 0.1 mM
EDTA, 250 mM NaCl, 25 mM β-mercaptoethanol) and
aliquoted into 100 μL in PCR tubes. To test the efficiency
of ligation under different concentrations of PEG-8000
[18], ligations were set up using 20 ng DNA from T4 Poly-
nucleotide Kinase treated/untreated samples with 5%,
12.5% and 15% PEG-8000 using T4 DNA Ligase Buffer,
50% PEG-8000 solution, BSA (15 μg), T4 DNA Ligase
(400 U) and modified, annealed linkers (75 μM), and were
incubated at 16°C for 16 h followed by purification using
the MinElute PCR Purification kit. The following steps
were performed in a thermocycler: 95°C for 3 min, 55°C
for 1 min, 0.1°C/sec to 48°C, 48°C for 3 min followed by
2°C decrements in temperature, holding for 3 min at each
step until 4°C was reached. Real-time PCR of the ligation
reactions was performed using iQ™ SYBR® Green Supermix
(Bio-Rad). Taq DNA Polymerase and PfuTurbo® DNA
polymerase (Agilent) were added to the supermix to re-
produce the LM-PCR conditions, as LM-PCR required a
non-hot-start DNA polymerase for initial fill-in of ligated
products. QPCR was performed in triplicate using KLM-
PCR Oligo_1 and in duplicate using a gene specific (Rbp3)
primer pair as a loading control for DNA in each reaction.
The cycling conditions were 72°C for 3 min for initial fill-
in, 94°C for 2 min for initial denaturation, followed by 35
cycles of (94°C for 15 sec, 95°C for 15 sec, 60°C for 30 sec,
72°C for 30 sec and 72°C for 30 sec for image capture) and
a disassociation curve. The relative fold-change between
the various ligation conditions (+kinase vs kinase at 5%
PEG, 12.5% PEG vs 5% PEG, 15% PEG vs 5% PEG, 12.5%
PEG/+kinase vs 5% PEG/-kinase and 15% PEG/+kinase vs
5% PEG/-kinase) were calculated and plotted for five rep-
licate experiments, along with the standard error of
the mean (Figure 1A). For the microarray samples, the
KLM-PCR conditions included phosphorylation of DNA
by T4 Polynucleotide Kinase prior to the blunting reac-
tion (see above), modified linkers and 13% PEG-8000
instead of 5% PEG-8000. Either 10 ng of fragmented
DNA (input) or 10 μL of methylation-enriched DNA in
100 μL Buffer EB (Qiagen) was treated with 10 U of
T4 polynucleotide kinase in 150 μL of 1X T4 DNA ligase
buffer. After 1 h incubation at 37°C, 1 U of T4 DNA poly-
merase, 10 μL of 10X NEBuffer 3, 10 μL 10 mM dNTPs
and 2 μL 10 mg/ml BSA in a volume of 50 μL were added
to a total volume of 200 μL and reactions were incubated
at 12°C for 20 min. Amplified DNA was quantified using a
NanoDrop (Additional file 1: Figure S1).
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Fragmented (input) DNA was labeled with Cy3, and
enriched (methylated) DNA was labeled with Cy5, using
the NimbleGen Dual-Color DNA Labeling kit (Roche)
according to the manufacturers’ instructions. Samples
were hybridized to the custom NimbleGen 2.1M feature
mouse CHARM microarray at the Johns Hopkins Med-
ical Institutions Deep Sequencing & Microarray Core Fa-
cility or the Johns Hopkins Bloomberg School of Public
Health Genomic Analysis and Sequencing Core Facility.
MeKL-chip data analysis
Analysis of the MeKL-chip data was performed using
the R/Bioconductor software for CHARM as previously
published [14,31]. In brief, this method used genome-
weighted smoothing of probes within genomic regions to
identify T-DMRs. Results from each NimbleGen CHARM
array contained two sets of raw data: input (untreated)
DNA and methyl-enriched DNA. Hybridization quality
was assessed by a signal score, which examined the num-
ber of untreated channel signal probes that ranked above
the background (anti-genomic control) probes. Successful
hybridization was indicated by a higher signal score (usu-
ally greater than 0.85). After Loess normalization within
samples for all control probes [31] and quantile normal-
ization between samples had been performed, the relative
methylation level for each probe was calculated as the ratio
of the methylated probe to the input probe signal. As pre-
viously described [14], a t-test was adopted to identify dif-
ferentially methylated probes between brain and retina
samples (from triplicate arrays). Triplicate arrays consisted
of either high-input (250 ng) or low-input (≤50 ng) retina
and brain groups. The t-statistic cutoff in this study was set
as P < 0.005. Consequently, T-DMRs were constituted by
neighboring differentially methylated probes. T-DMRs with
less than three probes were excluded from further analysis.
The definition of local CpG density by Pelizzola et al. [32]
was adopted to analyze the identified T-DMRs. In general,
the local CpG density of one nucleotide represents a
weighted (0 at the boundary and 1 at the center) count of
CpG sites surrounding the nucleotide, that is, 300 bp up-
stream and downstream from the nucleotide of interest (a
window size selected based on the average fragment size).
The local CpG density of a T-DMR was then obtained as
mean value of local CpG densities of all nucleotides within
the T-DMR. In addition, the observed-to-expected CpG ra-
tio (CpGO/E) of a T-DMR was calculated using the stand-
ard formula:
CpGO=E ¼ NCpG
NC  NG  L;
where NCpG, NC and NG are the number of CpGs, and nu-
cleotide Cs and Gs, respectively, and L is the length of the
T-DMR sequence.Pyrosequencing
Using the EZ DNA Methylation-Gold™ Kit (Zymo), 1 μg
of genomic DNA was bisulfite converted. Bisulfite-
converted DNA was eluted twice in 10 μL M-Elution
buffer and stored as 5 μL aliquots at −80°C. Genomic se-
quences surrounding the RefSeq genes were obtained
using the UCSC Genome Browser for Rgs20 (Gene ID:
58175), Hes2 (15206), Nfic (18029), Cckbr (12426) and
Six3os1 (100043902). Pyrosequencing primers were
designed (Additional file 2: Tables S2 and S3) within the
identified DMR locations using the PyroMark Assay De-
sign Software (Qiagen). PCR was performed using 1 μL
of bisulfite-converted DNA and HotStarTaq DNA Poly-
merase (Qiagen) under the following cycling conditions:
95°C for 15 min; 45 cycles of (94°C for 30 s, annealing
temperature from Additional file 2: Table S2 for 30 s,
72°C for 60 s); 72°C for 3 min; 4°C hold followed by stor-
age at −20°C. Amplicons were analyzed on a PyroMark
Q24 Pyrosequencer as per the manufacturer’s protocols
and methylation at the CpG sites was quantified using
the PyroMark Q24 software version 2.0.6.Additional files
Additional file 1: Figure S1. The KLM-PCR protocol. (A) Modification of
the universal adapter oligo sequence. The original LM-PCR oligo
contained a palindrome at the 3′ end [17]. Prevention of dimerization
through the disruption of the oligo palindrome increases the amount of
available oligo for KLM-PCR amplification. dNTPs are now the limiting
factor in the amplification. (B) NanoDrop quantification of the mean
micrograms of DNA produced after KLM-PCR. Bars represent the mean of
duplicate experiments from amplification of 10, 25, 50 and 250 ng
amounts of pre-enriched starting DNA, or 10 ng of unenriched (UE) DNA.
Error bars show standard deviation (n = 2).
Additional file 2: Table S1. Top 20 differentially methylated regions
identified between mouse retina and brain from 250 ng of starting DNA.
Table S2. PCR amplification primers used for pyrosequencing the top five
DMRs identified using MeKL-chip. Table S3. Sequencing primers used for
pyrosequencing validation of the top five DMRs identified using MeKL-chip.
Additional file 3: Figure S2. Relative CpG methylation in the retina
(red) and brain (blue) of the four other top T-DMRs (black boxes)
evaluated using MeKL-chip (top plots) and pyrosequencing validation of
the differential methylation (bottom graphs). See Figure 2C for
description of MeKL-chip results. Pyrosequencing of CpGs within the T-
DMR confirmed differential methylation (P < 0.001, Student’s two-tailed,
paired t-test) between the retina (red bars) and brain (blue bars) in a
second cohort of mice. Error bars show the 95% CI (n = 5).
Additional file 4: Figure S3. Pre-hybridization validation of enrichment
from low-input (10, 25 and 50 ng) enriched DNA from retina and brain
samples. The mixed effects regression model with a random intercept for
the measures from triplicate QPCR of two PCR amplifications of the same
sample were used to calculate the mean difference and standard error in
fold enrichment. (A) Post-enrichment, Rbp3 (grey bars) and Rho (black
bars) were enriched for methylated DNA in the brain samples for all
amounts of starting DNA, whereas no enrichment was observed in
unenriched (UE) DNA. (B) Post-KLM-PCR, QPCR showed maintenance of
the enrichment pattern for methylation in the brain samples for Rho
(black bars) and Rbp3 (grey bars) and no enrichment of the UE samples.
Additional file 5: Figure S4. MeKL-chip CpG site methylation profiles
of the Rgs20 region identified as a T-DMR (highest ranked, P < 10-16,
black box; lower ranked, P < 0.0091, dashed box) for the 250-ng
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previously shown in Figure 2. The 10 ng low-input sample at the same
region of Rgs20 is shown for direct comparison (lower plot) in brain
(blue) and retina (red). Each point is the relative percentage methylation for
1 probe in 1 sample. The 250 ng plot contains biological triplicates and blue
and red lines show the average methylation. The 10 ng plot contains one
biological sample. The T-DMRs are still detectable in the 10 ng low-input
sample.
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